摘要
目的:探讨多西他赛联合顺铂4 wk治疗晚期非小细胞肺癌方案的疗效和安全性。方法:经病理组织学或细胞学确诊的ⅢB期或Ⅳ期非小细胞肺癌病人26例,年龄在35-78 a,ECOG PS评分为0-2分;d 1,8 多西他赛37．5 mg·m-2,d 1-3顺铂75-100 mg·m-2,分3 d,均予静脉滴注。每4 wk重复,2个周期后评价疗效与不良反应,并随访生存期。结果:24例可评价疗效病人中,部分缓解(PR)8例,完全缓解(CR)1例,总有效率为38％。ECOG PS评分0-1分病人有效率明显高于ECOG PS评分2分病人。中位生存期为11 mo,1年生存率为50％。Ⅲ-Ⅳ度白细胞减少的发生率为20％。结论:多西他赛联合顺铂4 wk方案治疗晚期非小细胞肺癌安全且有效。
AIM：To investigate the effects and safety of 4 wk course docetaxel/cisplatin chemotherapy for advanced non-small cell lung cancer （NSCLC）. METHODS： Twenty-six patients with advanced NSCLC confirmed histopathologically as grade Ⅲ B or Ⅳ were enrolled with age ranging from 35 to 78 a and ECOG PS of 0-2. They were all taken docetaxel 37.5 mg·m^-2 on d 1 and d 8,cisplatin 75 - 100 mg·m^-2 on d 1 to d 3.The treatment schedule was recycled every 4 wk.The response and toxicity were evaluated by the end of two cycles with follow up of survival. RESULTS： Twenty-four out of 26 evaluated patients showed complete response （CR） and partial response （PR） in 1 patient and 8 patients,respectively with overall response rate of 38 %. The response rate in patients with ECOG PS of 0-1 was significiantly higher than that with ECOG PS of 2. Median survival period was 11 mo and 1 year-survival rate reached 50 %. The toxicities were mild including 20 % grade 3 and 4 leucopenia. CONCLUSION： Four-week regimen of docetaxel/cisplatin is effective and safe for advanced NSCLC patients.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第2期141-143,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
癌
非小细胞肺
药物疗法
多西他赛
顺铂
carcinoma, non-small cell lung, drug therapy
docetaxel
cisplatin
